RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CNS Pharmaceuticals Stock

CNS Pharmaceuticals Revenue 2024

CNS Pharmaceuticals Revenue

0 USD

Ticker

CNSP

ISIN

US18978H1023

WKN

A2PNH4

In 2024, CNS Pharmaceuticals's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The CNS Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2030e324.61-
2029e249.63-
2028e132.37-
2027e85.66-
2026e41.57-
2025e--
2024e--
2023--
2022--
2021--
2020--
2019--
2018--
2017--

CNS Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CNS Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CNS Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CNS Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CNS Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CNS Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CNS Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CNS Pharmaceuticals’s growth potential.

CNS Pharmaceuticals Revenue, EBIT and net profit per share

DateCNS Pharmaceuticals RevenueCNS Pharmaceuticals EBITCNS Pharmaceuticals Net Income
2030e324.61 M undefined207.65 M undefined0 undefined
2029e249.63 M undefined148.68 M undefined0 undefined
2028e132.37 M undefined48.92 M undefined0 undefined
2027e85.66 M undefined10.6 M undefined0 undefined
2026e41.57 M undefined-21.18 M undefined-489,997.77 undefined
2025e0 undefined-16.24 M undefined-530,830.9 undefined
2024e0 undefined-13 M undefined-1.16 M undefined
20230 undefined-18.87 M undefined-18.85 M undefined
20220 undefined-15.27 M undefined-15.27 M undefined
20210 undefined-14.49 M undefined-14.5 M undefined
20200 undefined-9.45 M undefined-9.46 M undefined
20190 undefined-3.83 M undefined-3.88 M undefined
20180 undefined-880,000 undefined-7.39 M undefined
20170 undefined-220,000 undefined-220,000 undefined

CNS Pharmaceuticals stock margins

The CNS Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CNS Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CNS Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CNS Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the CNS Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CNS Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CNS Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CNS Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CNS Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CNS Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CNS Pharmaceuticals Margin History

CNS Pharmaceuticals Gross marginCNS Pharmaceuticals Profit marginCNS Pharmaceuticals EBIT marginCNS Pharmaceuticals Profit margin
2030e0 %63.97 %0 %
2029e0 %59.56 %0 %
2028e0 %36.96 %0 %
2027e0 %12.37 %0 %
2026e0 %-50.95 %-1.18 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

CNS Pharmaceuticals Aktienanalyse

What does CNS Pharmaceuticals do?

CNS Pharmaceuticals Inc is an American pharmaceutical company specializing in the development and marketing of innovative therapies for patients with severe and life-threatening central nervous system disorders. The company was founded in 2017 and is headquartered in Houston, Texas. CNS Pharmaceuticals Inc's history began with the realization that there is an urgent need for new and more effective treatment methods for central nervous system tumors. The company's founders therefore identified promising new drugs based on the latest research findings and began testing them in clinical trials. CNS Pharmaceuticals Inc's business model focuses on innovative research and development of new drugs, as well as close collaboration with leading scientists and medical professional societies. The company aims to bring its medications to market quickly and cost-effectively, without compromising on quality or safety. The various divisions of CNS Pharmaceuticals Inc include research, development, production, and marketing of its drugs. The company has launched a variety of research projects aimed at developing new therapies for patients with brain tumors and other severe central nervous system disorders. One of CNS Pharmaceuticals Inc's most well-known products is Berubicin, a promising drug for the treatment of glioblastoma, a particularly aggressive type of brain tumor. Berubicin is a novel DNA-intercalating drug that is highly effective and has low toxicity. Clinical trials have already shown that Berubicin can extend the survival time of patients. Another important product of CNS Pharmaceuticals Inc is WP1244, a drug against glioblastoma based on an innovative technology that improves the uptake of drugs into cells. Preclinical studies have already shown that WP1244 is able to stop tumor growth and destroy cancer cells. CNS Pharmaceuticals Inc has a strong network of partner companies and distribution partners that help with the marketing and dissemination of its products. The company works closely with leading cancer centers and research institutions to further improve the effectiveness of its drugs and provide patients with a higher level of safety and quality of life. Overall, CNS Pharmaceuticals Inc has established itself as a dynamic and innovative company with a high level of expertise in the development of new drugs. The company aims to expand its position as a leading provider of therapies for patients with brain tumors and other severe central nervous system disorders, and to sustainably improve the quality of life of affected patients. CNS Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding CNS Pharmaceuticals's Sales Figures

The sales figures of CNS Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing CNS Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize CNS Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in CNS Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about CNS Pharmaceuticals stock

How much revenue did CNS Pharmaceuticals generate this year?

CNS Pharmaceuticals has achieved a revenue of 0 USD this year.

How much was the turnover of the company CNS Pharmaceuticals compared to the previous year?

The revenue of CNS Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of CNS Pharmaceuticals?

The revenue of CNS Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of CNS Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of CNS Pharmaceuticals so important for investors?

The revenue of CNS Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does CNS Pharmaceuticals pay?

Over the past 12 months, CNS Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CNS Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of CNS Pharmaceuticals?

The current dividend yield of CNS Pharmaceuticals is .

When does CNS Pharmaceuticals pay dividends?

CNS Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CNS Pharmaceuticals?

CNS Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of CNS Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CNS Pharmaceuticals located?

CNS Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von CNS Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CNS Pharmaceuticals from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did CNS Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of CNS Pharmaceuticals in the year 2023?

In the year 2023, CNS Pharmaceuticals distributed 0 USD as dividends.

In which currency does CNS Pharmaceuticals pay out the dividend?

The dividends of CNS Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CNS Pharmaceuticals

Our stock analysis for CNS Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CNS Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.